Capsida Biotherapeutics, Inc.
Clinical trials sponsored by Capsida Biotherapeutics, Inc., explained in plain language.
-
One-Shot gene therapy trial offers hope for kids with devastating brain disease
Disease control TerminatedThis study is testing a single-dose gene therapy called CAP-002 in children with STXBP1 encephalopathy, a rare genetic disorder that causes severe developmental delays and seizures. The main goals are to see if the treatment is safe and if it can improve children's development, m…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 04, 2026 06:06 UTC
-
One-Shot gene therapy tested to halt Parkinson's progression
Disease control TerminatedThis early-stage trial is testing a new, one-time gene therapy called CAP-003 in adults with Parkinson's disease caused by a specific genetic change (GBA1 mutation). The main goals are to see if the treatment is safe and to look for early signs that it might help control the dise…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC